Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Boehringer's "One Medicine Platform," replaces over 20 legacy platforms. The initiative unifies medicinal development processes and data sources into a connected ecosystem, with the aim of ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...

"Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across ...

INGELHEIM, Germany and PLEASANTON, Calif., March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform ...